CHICAGO / Sep 22, 2023 / Business Wire / The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC), a leading medical technology, pharmaceutical diagnostics, and digital solutions innovator, today declared a cash dividend of $0.03 per share of Common Stock for the third quarter of 2023 payable on November 15, 2023 to all shareholders of record as of October 20, 2023.
About GE HealthCare
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.
| Last Trade: | US$81.76 |
| Daily Change: | -1.16 -1.40 |
| Daily Volume: | 3,609,013 |
| Market Cap: | US$37.340B |
November 12, 2024 October 30, 2024 October 21, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
